The content on this site is intended for healthcare professionals only
Selecting appropriate first line lung cancer therapy
Published: 8 Jul 2009
Views: 15791
Dr Paul Bunn - University of Colorado, Denver, USA
erlotininb, cetuximab or gefitinib for lung cancer in pill form- less toxic and better tolerated, better survival for patients with EGFR gene mutation.
- Categories:
- Lung & pleura
- Biology
- Targeted molecules
Related Videos
From clinic to practice in NSCLC patients with exon 20 mutations
Prof Nicolas Girard - Institut Curie, Paris, France
13 Sep 2022
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squ...
Dr Silvia Novello - University of Turin, Turin, Italy
11 Sep 2022
Scientists discover mechanism of action and an actionable inflammatory axis for ...
Prof Charles Swanton - The Francis Crick Institute, London, UK
10 Sep 2022
WCLC 2022: Highlights
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
31 Aug 2022
OncoAlert and ecancer weekly round up for August 8th - 14th, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
15 Aug 2022
What's new in molecular targeted treatments for EGFR mutant NSCLC
Dr Keith Kerr, Dr Melina Marmarelis, Prof Amanda Tufman and Dr Jordi Remón Masip
12 Aug 2022
Topics under discussion at the WCLC 2022 presidential symposium
Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
9 Aug 2022
ASCO Direct Highlights 2022: lung cancer highlights
Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA
9 Jul 2022
Locally and advanced immunotherapy developments and new agents in lung cancer
Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA
9 Jul 2022